drugset / Trial / NCT00631969

Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction

NCT00631969 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.

Timeline

Start
2008-04
Primary completion
2009-01
Completion
2009-01

Outcome

Met primary endpoint

paper Vardenafil ODT therapy was statistically significantly superior to placebo for all primary (IIEF-EF, SEP2, SEP3) and secondary efficacy measures (all P < 0.0001). PMID 20233275 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 10 mg Oral

Indications